XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:        
Total revenue $ 90,036 $ 72,597 $ 178,313 $ 139,707
Cost of revenue, exclusive of depreciation and amortization shown below:        
Total cost of revenue, exclusive of depreciation and amortization 67,507 56,631 135,031 109,352
Operating expenses:        
Research and development 1,777 3,243 3,056 7,208
Sales and marketing 2,732 2,172 5,185 4,821
General and administrative 17,599 15,150 34,176 31,028
Change in fair value of contingent consideration receivable 3,350   3,750  
Long-lived asset impairment charge       4,062
Depreciation and amortization 6,103 5,489 12,303 11,231
Total operating expenses 31,561 26,054 58,470 58,350
Loss from operations (9,032) (10,088) (15,188) (27,995)
Other income (expense):        
Interest expense, net (1,144) (2,444) (2,409) (4,713)
Other income 566   1,018  
Total other expense, net (578) (2,444) (1,391) (4,713)
Loss from continuing operations before income taxes (9,610) (12,532) (16,579) (32,708)
Income tax expense 133 159 238 375
Net loss from continuing operations (9,743) (12,691) (16,817) (33,083)
Net loss from discontinued operations, net of tax (108) (36,919) (8,932) (44,720)
Net loss $ (9,851) $ (49,610) $ (25,749) $ (77,803)
Net loss per share:        
Net loss per share from continuing operations, basic (in dollars per share) $ (0.38) $ (0.53) $ (0.66) $ (1.38)
Net loss per share from discontinued operations, basic (in dollars per share)   (1.54) (0.35) (1.87)
Total net loss per share, basic (in dollars per share) (0.38) (2.07) (1.01) (3.25)
Net loss per share from continuing operations, diluted (in dollars per share) (0.38) (0.53) (0.66) (1.38)
Net loss per share from discontinued operations, diluted (in dollars per share)   (1.54) (0.35) (1.87)
Total net loss per share, diluted (in dollars per share) $ (0.38) $ (2.07) $ (1.01) $ (3.25)
Weighted average common shares outstanding:        
Weighted average common shares outstanding, basic (in shares) 25,422,032 23,959,726 25,333,137 23,913,050
Weighted average common shares outstanding, diluted (in shares) 25,422,032 23,959,726 25,333,137 23,913,050
Medication        
Revenue:        
Total revenue $ 69,626 $ 55,892 $ 138,376 $ 106,865
Cost of revenue, exclusive of depreciation and amortization shown below:        
Total cost of revenue, exclusive of depreciation and amortization 53,554 43,384 106,636 82,936
Technology-enabled solutions        
Revenue:        
Total revenue 20,410 16,705 39,937 32,842
Cost of revenue, exclusive of depreciation and amortization shown below:        
Total cost of revenue, exclusive of depreciation and amortization $ 13,953 $ 13,247 $ 28,395 $ 26,416